Two Days That Mapped the Next Phase of APAC Dealmaking
"Oncology remained the centre of gravity, but with striking mechanistic diversity. Sequencio Therapeutics, a CK Life Sciences subsidiary, presented therapeutic cancer vaccines aimed at durable immune-controlled remission. FoRx Therapeutics of Switzerland brought a clinical-stage PARG inhibitor, FORX-428, into the room with a Phase 1 readout expected in the second half of 2026. CytoDyn presented leronlimab, its CCR5-targeting antibody, in heavily pretreated metastatic colorectal cancer, and Rakuten Medical showcased its Alluminox photoimmunotherapy platform. On Day 2, Singapore's own Albatroz Therapeutics presented its Calnexin-targeted antibody approach spanning oncology and autoimmune disease, and Australis Pharmaceuticals arrived weeks away from a first-in-human dose escalation trial in Adelaide."
https://www.biospectrumasia.com/news/29/28309...aking.html